Exelixis | EXEL - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Agios Pharmaceuticals USD 717.67M 117.18M 2026-06
Akebia Therapeutics USD 229.55M 13.93M 2026-06
Amgen USD 34.96B 3.49B 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
Bayer EUR 33.64B 1.66B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Cytokinetics USD 1.21B 369.02M 2026-06
Eisai JPY 883.01B 121.38B 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Exelixis USD 1.25B 42.18M 2026-06
Genmab DKK 2.8B 228M 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Incyte USD 6.03B 542.31M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
MacroGenics USD 321.69M 139.16M 2026-06
Merck USD 36.68B 1.66B 2026-06
Moderna USD 5.82B 45M 2026-06
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 27.35B 744M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Puma Biotechnology USD 143.58M 7M 2025-09
Sanofi EUR 30.16B 789M 2026-03
Takeda JPY 3.15T 59.77B 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Xencor USD 523.21M 40.36M 2026-06